Tag: MACE

digestive system
Latest News Other Categories Research & Trials

Efpeglenatide, a novel GLP-1 receptor agonist, reduces cardiovascular events and progression of chronic renal failure in type 2 diabetes

CardioNewsUK 7 July 2021

By Ahmed El-Medany Weekly subcutaneous injections of efpeglenatide, a novel exendin-based GLP1-RA, have been shown to reduce the risk of major adverse cardiovascular events (MACE)…

View More Efpeglenatide, a novel GLP-1 receptor agonist, reduces cardiovascular events and progression of chronic renal failure in type 2 diabetes
exercise in park
Research & Trials

Physical activity reduces cardiovascular risk and all-cause mortality if performed during leisure time, not working hours

CardioNewsUK 17 April 2021

By Ahmed El-Medany The contemporary Copenhagen General Population Study recently published their findings in the European Heart Journal. This large study, which was established in…

View More Physical activity reduces cardiovascular risk and all-cause mortality if performed during leisure time, not working hours